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ABSTRACT A cDNA sequencing project was initiated to
characterize gene expression in human bone marrow and
develop strategies to isolate novel genes. Forty-eight random
cDNAs from total human bone marrow were subjected to
single-pass DNA sequence analysis to determine a limited
complexity ofmRNAs expressed in the bone marrow. Overall,
8 cDNAs (17%) showed no sim to known sequences.
Information from DNA sequence analysis was used to develop
a differential prescreen to subtract unwanted cDNAs and to
enrich for unknown cDNAs. Forty-eight cDNAs that were
negative with a complex probe were subject to single-pass DNA
sequence determination. Of these prescreened cDNAs, the
number of unknown sequences increased to 23 (48%). Un-
known cDNAs were also characterized by RNA expression
analysis using 25 different human leukemic cell lines. Of 13
unknown cDNAs tested, 10 were expressed in all cell types
tested and 3 revealed a hematopoietic lineage-restricted ex-
pression pattern. Interiy, while a total of only 96 bone
marrow cDNAs were sequenced, 31 of these cDNAs represent
sequences from unknown genes and 12 showed ificant
similarities to sequences in the data bases. One cDNA revealed
a si nt similit to a serine/threonine-protein kinase at
the amino acid level (56% Identity for 123 amino acids) and
may represent a previously unknown kinase. Differential
screening techniques coupled with single-pass cDNA sequence
analysis may prove to be a powerful and simple technique to
eamine developmental gene expression.
Large-scale cDNA sequencing is an important part of the
Human Genome Project. The sequence identification of all
expressed cDNAs will benefit a wide variety of research,
including physical mapping, gene structure analysis, and the
identification ofthe genetic basis for many diseases (1, 2). Of
the approximately 100,000 human genes, an estimated 29,000
human sequences are present in the data bases. To isolate
every human gene, it will be necessary to construct cDNA
libraries from a variety of tissues and developmental states.
In addition, the use of sophisticated cDNA library construc-
tion and library screening techniques will also be necessary
to decrease cDNA sequence redundancy and increase the
probability of isolating rare cell-specific cDNAs. It is likely
that each tissue source will pose unique problems before all
human cDNAs are isolated. Thus combinations of cellular
enrichment techniques, subtracted or normalized libraries,
and differential screening will be necessary to isolate rare
human mRNAs. Recent human cDNA sequencing projects
have been successful at isolating genes expressed in the brain
(1, 3), testis (4), T cells (5), and retinal epithelium (6).
Bone marrow (BM) is a complex tissue containing different
cell types and cells at different stages of differentiation. The
major cellular groups are hematopoietic cells and stromal
cells. In addition, BM contains rare hematopoietic stem cells
(HSC), the precursors of erythroid, myeloid, and lymphoid
cell populations. Only a fraction of the genes which control
the growth and differentiation of hematopoietic cells within
human BM have been identified. Moreover, the complete
DNA sequence information, chromosomal location, and cell-
type expression patterns of BM genes will be a valuable
resource for understanding the molecular basis of BM-
derived disorders.
This project was initiated to determine the complexity of
total BM sequences and determine the efficacy of differential
screens to remove redundant sequences and thereby enrich
for rare lineage-specific mRNAs. Previous large-scale single-
pass cDNA sequence analysis has resulted in the generation
of over 20,000 expressed sequence tags (ESTs), the majority
of which are from human cDNA libraries. "EST" has
become an unfortunate nomenclature, since the presence of
these sequences in cDNA libraries does not guarantee that
they are derived from true expressed transcripts. Contami-
nants may arise from genomic DNA, incomplete splicing, or
low-level contamination from various microorganisms. To
circumvent these problems we have tested coupling single-
pass DNA sequence determination to rapid expression stud-
ies on Northern blots. Unique cDNA sequences with re-
stricted expression patterns will be subject to further struc-
ture/function analysis. We show that with as few as four runs
on an automated DNA sequencer, or 96 cDNAs sequenced,
31 of these may correspond to previously unknown genes,
and one ofthese is likely to encode a serine/threonine kinase.
MATERIALS AND METHODS
Construction and Isolation of Human BM cDNAs. Human
BM was obtained from a healthy male and a healthy female
donor. Total RNA was isolated (7) and poly(A)+ RNA was
purified by two passes of oligo(dT) chromatography. One-
half microgram of poly(A)+ RNA was used to synthesize
cDNA with random hexamers as described by the TimeSaver
cDNA synthesis kit (Pharmacia). Random hexamers (50 ng)
were used for 2 hr of cDNA synthesis and oligo(dT) was
added during the last hour. Complementary DNAwas ligated
into M13mpl8 and stored at -700C. Transformations were
performed with 0.5 pl of the 35-gl ligation mixture, using
Abbreviations: BM, bone marrow; PSBM, prescreened bone mar-
row; EST, expressed sequence tag; GRAIL, Gene Recognition and
Analysis Internet Link.
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supercompetent XL1-Blue cells (Stratagene) and titrated to a
density of 500 plaques per plate. Individual plaques were
picked and tested for inserts by PCR using M13 (IacZ)
primers (BV40, 5'-ACGTTGTAAAACGACGGCCAGT-3';
BV41, 5'-GAAACAGCTATGACCATGATTA-3').
Differential Hybridization. For differential screens, 48 BM
cDNAs were sequenced and subject to DNA sequence anal-
ysis. Twenty-seven of these identified BM cDNAs were
chosen to represent known human sequences and unwanted
cDNAs such as globin. Two probes were prepared and mixed
in the final hybridization. The first probe consisted of gel-
purified PCR products of the 27 BM cDNAs with known
sequences, pooled and labeled by random priming. The
second probe was synthesized by using 2.4 Mg of HeLa cell
poly(A)+ RNA and avian myeloblastosis virus reverse tran-
scriptase (Molecular Genetics) to a specific activity of 1.5 x
107 cpm/,ug, and the entire cDNA reaction mixture was
added to the hybridization mixture with the first BM probe.
Differential hybridizations, of 104 M13 phage plated to a
density of -500 plaque-forming units per plate, were per-
formed in 5x SSPE/Sx Denhardt's solution containing
salmon sperm DNA at 100 ,g/ml, 10%o dextran sulfate, and
0.1% SDS for 16 hr at 580C. Filters were washed once in 2x
SSC/0.1% SDS at 250C and three times in 0.2x SSC/0.1%
SDS at 650C. (lx SSPE = 150 mM NaCl/10 mM sodium
phosphate, pH 7.4/1 mM EDTA; lx Denhardt's solution =
0.02% bovine serum albumin/0.02% Ficoll/0.02% polyvi-
nylpyrrolidone; lx SSC = 150 mM NaCl/15 mM sodium
citrate, pH 7.0.) Plates contained 5-10%o background nonre-
combinants.
RNA Gel Blot Hybridization. Total RNA was isolated from
cell lines (7) and 20 ug was electrophoresed on formalde-
hyde/1% agarose gels. RNA was transferred to nitrocellulose
and probed with gel-purified PCR products labeled by ran-
dom priming. Probes were added to hybridization mixtures
containing 50% deionized formamide, 5x SSC, lx Den-
hardt's solution, 50 mM sodium phosphate at pH 7.0, and
salmon sperm DNA at 0.25 mg/ml and hybridized for 12-16
hr at 420C. Blots were washed in 2x SSC/0.1% SDS at room
temperature for 30 min and in 2x SSC/O.1% SDS at 600C for
30-60 min. Cell lines were kind gifts from the following
sources: KG1 (8, 9) and M07E, provided by D. Golde
(Sloan-Kettering); AF10, provided by A. Saxon [University
of California, Los Angeles (UCLA)]; Jurkat (10), provided by
W. Clark (UCLA); CCRF-CEM (11), provided by C. Uitten-
bogaart (UCLA); PLB 985 (12), provided by S. Smale
(UCLA); and BV173 (13) and IMR 5, provided by A. Van
Herle (UCLA). Also used were ALL-1 (14) and HEL (15).
cDNA Sequence Determination and Data Base Analysis. For
single-run DNA sequence determination, M13 DNA was
prepared using a PEG miniprep procedure starting with 1.0
ml of infected culture. Sequence determination was per-
formed by using Taq DNA polymerase, M13 fluorescent
primers (Applied Biosystems), and the Applied Biosystems
catalyst. Reactions were run on the Applied Biosystems 373
automated DNA sequencer. Approximately 400 bases were
compared with nonredundant European Molecular Biology
Laboratory and GenBank data bases (version 73), using
BLAST (16). Sequences were also translated and used to
search the protein data bases (Protein Identification Re-
source), using the BLASTX sequence analysis program. DNA
sequences that were determined to be unknowns from the
BLAST analysis were subjected to further analysis using the
FASTA program (17). In addition, all unknown sequences
were sent by electronic mail to GRAIL (Gene Recognition
and Analysis Internet Link) (18). Predicted exons were
translated and further protein analysis was performed by
using the FASTA program.
RESULTS
Partial DNA Sequence Analysis of BM cDNAs. Random
shotgun DNA sequencing ofcDNAs is straightforward and is
based upon the assumption that if the sequence was prepared
from mRNA, it represents an expressed gene. The drawbacks
of limited shotgun sequencing are the loss of expression
information, possible sequencing of noncoding regions, and
the generation of sequence data from different regions of the
same transcript. We are beginning a cDNA sequencing
project using cDNAs isolated from human BM. Since we are
interested in isolating rare mRNAs that are expressed by the
developing hematopoietic system, we are evaluating combi-
nations of cDNA library prescreening coupled with rapid
methods for expression analysis. Forty-eight BM cDNAs
were subject to single-pass DNA sequence determination.
Eight (17%) of these represented cDNA sequences not found
in searching the GenBank data bases, using the BLAST
sequence analysis program (Table 1). The major mRNA
expressed in total BM was determined to be globin. Globin
was found to be present in 23% of the cDNAs sequenced.
Globin mRNA has been measured at 3% of murine reticulo-
cyte RNA, and up to 22,600 copies of globin mRNA have
been found per cell (19). Our result may be higher than
expected given a limited cDNA sample size. Other known
mRNAs observed in the random library include mitochon-
drial genes, ribosomal sequences, and repeats. Additional
abundant sequences were observed that may be unique to
BM-derived cDNAs. In addition to globin, these abundant
BM mRNAs include eosinophil basic protein and immuno-
globulins.
Initial cDNA sequencing and analysis of the total BM
library revealed problems associated with large-scale se-
quencing, such as the repetitive sequencing of common
"housekeeping" and other abundant mRNAs. To eliminate
these abundant unwanted sequences and increase the number
of rare, cell-specific, and possibly unknown sequences, a
differential screening strategy was tested. A complex probe
consisting of two cDNA mixtures was designed to eliminate
abundant sequences. This probe contained labeled cDNAs
from the known BM sequences (Table 1) and labeled cDNA
Table 1. Comparison of BM and prescreened BM (PSBM) DNA
sequence data to nucleic acid data bases
BM cDNAs PSBM cDNAs
Type of sequence match Number %* Number %*
Unknown sequence/no match 8 17 23 48
Human sequences 8 17 9 19
Immunoglobulin 2 3
Eosinophil basic protein 2 0
Others 4 6
Nonhuman sequencest 2 4 2 4
Unwanted sequences 30 63 14 29
Globin 11 3
Mitochondrial 6 0
Ribosomal 3 3
Actin/tubulin 3 0
Alu repeats 2 5
Otherst 5 3
Total 48 48
BM and PSBM cDNA sequence data, generated from one se-
quence run, were compared with sequences in a nonredundant DNA
data base by using the BLASTN (nucleic acid) and BLASTX (protein)
analysis programs.
*Percent of 48.
tNonhuman data base matches indicate similarities to nonhuman
DNA sequences, the lowest being 69-/178bp and the highest
87%/40 amino acids.
*Other sequence data include pieces of vector sequences (nonre-
combinants) and poly(A) runs.
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derived from HeLa cells. The HeLa probe was to identify
abundant sequences present in rapidly growing human cell
lines that might have been missed in our initial BM cDNA
sequencing. Since complex probes generated from total
mRNA populations cannot identify rare sequences, this
screen should label abundant sequences (-0.2%). The two
probes were mixed and hybridized to the total BM library.
Approximately 53% of the M13 plaques appeared as slight to
no hybridization. When more conservative criteria were
used, 10% of the M13 plaques were negative. Following the
differential screen, plaques that failed to hybridize with the
complex probe were isolated. Forty-eight of these PSBM
cDNAs were subject to limitedDNA sequence determination
(Table 1). As expected, the'prescreen increased the unknown
cDNA sequences from 17% to 48%. The percentage of
cDNAs with data base matches to known human sequences
and significant matches to nonhuman genes were unchanged
after the differential prescreen. The number of unwanted
sequences decreased from 63%'to 29%. Interestingly, globin
sequences were not completely'removed. The number of
sequences containing Alu repeats were also slightly increased
after the prescreen. This may reflect the increased sequence
complexity derived from unspliced poly(A)+ nuclear se-
quences.
For data analysis, cDNA sequences were first examined
for similarities to known genes by using the BLAST program
for nucleic acids. In addition, all six reading frames were
examined for similarities to proteins by using the BLASTX
program. To examine the accuracy of one-pass DNA se-
quence determination, six cDNAs encoding known human
sequences were aligned, using both BLAST and FASTA se-
quence analysis programs. The average BLAST alignment was
95 ± 5% in 292 bases and the FASTA average was 92 ± 6% in
356 bases. The alignment capabilities of the FASTA program
were also used to test whether the sequences of unknown
cDNAs were redundant. Cross-sequence analysis revealed
that the highest overlap between unknown cDNAs was 39%6
in 621 bases. Therefore it is unlikely that an abundant
unknown transcript was sequenced multiple times, unless the
cDNAs prepresent nonoverlapping sections of abundant un-
known clones. The sequences of 15 random unknown cDNAs
were also analyzed to determine whether they contained
open reading frames. All of these cDNAs had open reading
frames, with an average length of 206 ± 60 bases.
Once BLAST analysis failed to reveal significant similarities
between cDNA sequences and sequences in the data bases,
the unknown sequences were then subject to further analysis,
including GRAIL and FASTA. Twenty-two sequences from
unknown cDNAs were sent to the GRAIL system for puta-
tive exon prediction. The GRAIL system uses a multiple
sensor neural network to identify protein-coding regions of at
least 100 bases and has proven to accurately predict exons
89%o of the time (18). Eight of the 22 cDNAs examined by
GRAIL contained potential exons (Table 2). One explanation
why many of the sequences failed to contain predicted
protein-coding regions may be that these sequences are
derived from noncoding regions. These contributions could
be from 3' or 5' untranslated regions or from incompletely
spliced poly(A)+ RNAs, which are frequently observed in
BM cDNA libraries. The quality of the exon predictions
according to GRAIL varied equally from "excellent" to
"good." Since protein data base searches are more sensitive
than nucleic acid searches, the translated protein sequences
ofpredicted exons following GRAIL analysis were examined
for similarities to known proteins by using the FASTA pro-
gram. While this exon analysis regime failed to find a signif-
icant similarity to a known sequence, one cDNA exhibited
short and multiple similarities to Na/K-ATPases (data not
shown). Overall, the most important criterion to prioritize
unknown cDNAs for further analysis is a significant BLASTX
Table 2. Exon prediction of unknown BM cDNAs by
using GRAIL
Clone Strand Probability* Frame Qualityt ORF
BM1 F 0.76 3 Excellent 318-525
PSBM11 F 0.76 1 Excellent 136-214
PSBM19 F 0.85 3 Excellent 1-286
PSBM23 R 0.85 2 Excellent 1-170
PSBM27 R 0.82 2 Good 161-400
PSBM38 R 0.77 3 Good 261-555
PSBM41 R 0.71 3 Good 432-480
PSBM46 F 1.00 1 Good 1-241
PSBM46 R 0.79 2 Good 1-281
GRAIL uses a multiple-sensor neural network to identify coding
exons of at least 100 bp in human DNA. Results shown are from 22
unknown cDNA sequences submitted to GRAIL by electronic mail.
F, forward strand; R, reverse strand; ORF, open reading frame (base
pair numbers).
*Probability score greater than 0.5 identifies a region with protein-
encoding potential.
tQuality equals the GRAIL systems interpretation of raw data,
taking- into account strand, probability, frame, and ORF data.
(protein) similarity. However, the presence of predicted
exons and multiple weak similarities to known genes can also
be used to prioritize unknown cDNAs for -further RNA
expression analysis employing Northern blots.
RNA Expression Anaysis of Unknown cDNAs. Following
DNA sequence analysis, unknown cDNAs were tested for
expression against a panel of human leukemic cell lines.
These cell lines were chosen to represent a variety of
different hematopoietic cell types and differentiation states,
including multipotent cell lines. First, PCR products of
cDNAs were labeled and tested onRNA blots, using a limited
number of cell lines. This preliminary screen was used to
quickly assay whether the expression was restricted to a cell
type or was ubiquitously expressed among all cell lines
tested. Following this preliminary screen, the strategy was to
increase the number of cell lines tested and probe with
cDNAs that exhibited restricted or no expression. Of 13
unknown cDNAs tested, 10 were expressed in all cell lines
tested and 3 revealed a restricted expression pattern (Fig. 1).
In addition, one cDNA, PSBM6, exhibited two transcripts on
RNA blots. Further analysis of the 3 cDNAs with restricted
expression revealed major but not exclusive expression in
early myeloid cell lines. This may reflect the predominance
of myeloid cells over erythroid and lymphoid cells in nucle-
ated BM populations (20). One caveat concerning using
mRNA from continuous cell lines is that aberrant gene
expression may limit their value to assign gene expression to
defined cell types. As a consequence, it becomes necessary
to include multiple cell lines representing the same lineage or
state of differentiation on RNA blots. However, the ease in
growing large quantities ofthese cells to isolate mRNA to use
in RNA blots makes these cell lines ideal for an initial
prescreen. To characterize lineage-specific expression fur-
ther, it will be necessary to use panels of normal human BM
and peripheral blood cells and to enrich for specific cell types
either by sorting or by selective culture conditions. In addi-
tion, further analysis will include complete DNA sequence
determination and chromosomal mapping.
DNA Sequenc Analysis and the Idendfication of a Protein
Kinae. Single-pass DNA sequence analysis of96BM cDNAs
chosen by random selection and differential screening re-
vealed known human genes, known genes originally isolated
in other species, and unknown cDNA sequences. cDNAs
with significant similarities to nonhuman genes may repre-
sent the human equivalents of these genes. As an example,
the translation of BM9 revealed 126/141 (89%) amino acid
similarity to mouse Tum p198, a transplantation antigen
Cell Biology: Orr et al.
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FIG. 1. Northern blot analysis of individual BM cDNAs. Leu-
kemic cell lines used were as follows: multipotent, BV173 (lane 1);
pre-B lymphoid, ALL-1 (lane 2) and plasma cell AF10 (lane 3); T
lymphoid, CEM (lane 4) and Jurkat (lane 5); myeloid, KG-1 (lane 6),
megakaryocytic M07E (lane 7), myelomonocytic PLB 985 (lane 8),
and HEL (lane 9); and nonhemopoietic, neuroblastic IMR-5 (lane
10). (A) Northern analysis ofcDNAs that are generally expressed in
leukemic cell lines. (B) Northern analysis of cDNAs expressed in a
cell-lineage-restricted expression pattern. (C) Northern analysis of
PSBM6, a probable new kinase, demonstrating two transcripts in the
AF10 cell line.
expressed by the P815 mastocytoma (data not shown) (21). Of
the unknown or unique cDNA sequences, 16 exhibited
significant similarities to known genes in the data bases
(Table 3). Interestingly, with an estimated >20,000 unknown
cDNAs or EST sequences present in the data bases, only 1
of the 96 BM cDNA sequences exhibited significant similar-
ities to an EST. This may reflect gene expression differences
in the brain, where most of the ESTs have been derived,
versus the BM. Moreover, since the majority of the ESTs
were generated from libraries that used oligo(dT) as a primer,
a large percentage of ESTs may correpond to 3' untranslated
sequences. We have chosen random primers to synthesize
cDNA of moderate size to increase the possibility of gener-
ating sequences from exons and thus aid in the identification
of novel genes.
Of the three cDNAs that exhibited lineage-restricted ex-
pression patterns by Northern analysis, only one revealed
any significant similarity to a known gene. BM10, a 4.6-kb
transcript expressed primarily by B lymphoblastoid cells, has
significant similarity to a pig gene expressed during hepatic
stress (Fig. 2).
Of the 16 cDNAs that exhibited significant similarities to
known genes, one cDNA was of particular interest. PSBM6
was observed to be similar to protein kinase sequences on
both the nucleic acid and protein level. In addition, multiple
significant similarities to other kinases were present through-
out the sequence. The highest similarity was a 56%/123
amino acid identity to human p78 (Fig. 2). This kinase is an
unpublished data base entry described as a 78-kDa marker
lost in a chemically induced transplantable carcinoma and
related to serine/threonine-protein kinases. Therefore this
cDNA probably encodes a nonreceptor kinase that may
catalyze protein phosphorylation in response to second mes-
sengers.
SUMMARY AND CONCLUSIONS
cDNA Analysis. Recently large-scale cDNA sequencing
projects have contributed thousands of short (>150- to 500-
bp) cDNA sequences to the data bases (1, 3, 22). We have
sequenced 98 cDNAs corresponding to four runs on the
Applied Biosystems 373 DNA sequencer or 10 manual se-
quencing gels. This limited scale can be easily accomplished
by most laboratories. Of these 98 cDNAs sequenced, 31
cDNA sequences corresponding to unknown genes were
isolated. While the percentage ofunknown cDNA sequences
isolated will vary with different tissues and even different
libraries of the same tissue, the identification of a previously
unknown kinase demonstrates that shotgun cDNA sequenc-
ing in BM revealed novel cDNAs with significant sequence
similarities to known genes at a frequency of 1%. Moreover,
even a limited sequencing approach, when coupled to ex-
pression analysis, can reveal genes with restricted expres-
Table 3. Unknown BM cDNAs and PSBM cDNAs with significant similarities to known genes
cDNA Known gene or product Overlap %
clone Accession Description Species length identity
BM1 YSCMTCG Mitochondrial DNA Yeast 39 nt 76
BM3 B39057 Amelogenin Human 28 aa 60
BM9 M51528 ATP phosphotransferase Rat 255 nt 81
BM10 PIGHEP1 Unidentified hepatic mRNA Pig 67 nt 85
BM22 HUMACROD Acrosin gene, 3' end Human 16 aa 75
BM26 M73998 CAP18 protein mRNA Rabbit 178 nt 69
BM28 M31166 TNF-inducible mRNA Human 24 aa 79
PSBM2 HSB37G022 EST partial cDNA sequence Human 222 nt 9
PSBM3 SCMP48EGG p48 eggshell protein gene S. mansoni 17 aa 29
PSBM6 HUMP78A Protein p78 mRNA Human 123 aa 56
PSBM12 BOVRHOGDI Dissociation inhibitor of rho Bovine 302 nt 72
PSBM19 HSBBICP4A Herpesvirus transcription control protein Bovine 45 aa 28
PSBM28 M92295 vy and y2 globin Gorilla 52 nt 76
PSBM45 PFAMSAAAC Major merozoite surface antigen Plasmodium 64 nt 70
PSBM46 M78084 cDNA clone HHCP Human 182 nt 63
PSBM48 RATASI Amino acid starvation-induced protein Rat 57 aa 59
BLASTN and BLASTX results ofunknown BM cDNAs with similarities to known genes with a P(N) c 0.01. The P(N) value
represents the probability of a score occurring by chance, given the size of the sequence searched and the size of the data
base. The yeast is Saccharomyces cerevisiae; TNF, tumor necrosis factor; S. mansoni, Schistosoma mansoni.
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A
BM10
PIGH
BM1 0
PIGH
140 150 160 170 180 190
TCATGCCCAGTTAACTTATTTACAATATTTAAGTTCTCTGCTTCTGCATTTGGTTGGTTT
ACGATTGTTACCACGCGCCATTGGTTGCGCAAGTTTTCTGCTTCTGCTTTGGGTGGGTTT
1060 1070 1080 1090 1100 1110
200 210 220 230 240
CCTGAAG--- CGCNCCCTGTGAATAACAGGTGGCTTTT--CATGGATG ----TCTCTA--
CCTGAAGGCCCGGCCCCTGTTCATCTGAGGTGCCTTCTAGAAGGAATGTGCCTCTCTAGT
1120 1130 1140 1150 1160 1170
250 260 270 280 290 300
GTCAGAGAAAAATGATAAAGGCTTAAATTGAGGATTAACAGAAGCAGATTAACCTCAGAA
GTTGGGGAGGAACTGT-AGTGCTGCAACCGAGGATTAACAGAAGCAGATTAACCTCAAAA
1180 1190 1200 1210 1220
BM10
PIGH
BM1 0
PIGH
310 320 330
ATCCTGTCTGGCTGGCAGATTTCAAGTAA
AACCCTCCTGGCCGGCAGATTTCAAGTTT
1240 1250
340 350 360
B
PSBM6: 16 RTLGKGNFAVVKLARHRVTKTQVAIKIIDKTRLDSSNLEKIYREVQLMKLLNHPHIIKLY 195
+T+GKGNFA VKLARH +T +VAIKIIDKT+L++++L+K++REV++MK+LNHP+I+KL+
HUMP78A: 60 KTIGKGNFAKVKLARHILTGREVAIKIIDKTQLNPTSLQKLFREVRIMKILNHPNIVKLF 119
PSBM6: 196 QVMETKDMLYIVTEFAKNGEMFDYLTSNGHLS-NEARKTFWQILSAVEYCHDHHIVHRDLXTE 384
+V+ET LY++ E+A G +FDYL ++G++ +EAR F+QI+SAV+YCH+ +IVHRDL +E
HUMP78A: 120 EVIETQKTLYLIMEYASGGKVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLKAE 182
sion. In human BM this may be as high as 20% and may be
a consequence ofthe variety of cell types present in total BM.
Other criteria for the success of shotgun cDNA sequencing
projects are the quality ofthe library and the techniques used
to enrich for novel sequences. This total BM cDNA library
was constructed and sequenced without amplification. Suc-
cess can be easily monitored by the lack ofrare mRNAs being
sequenced with high redundancy. The other important cri-
teria are the technique or combination of techniques used to
enrich cDNA populations for novel sequences. These include
cDNA library normalization (23), subtraction (3), and differ-
ential screening (22). We employed a combination differential
screen to remove abundant sequences; this technique can be
extended to include multiple rounds of differential screens to
remove clones that have been previously sequenced. An
additional advantage of differential prescreens is the removal
ofredunant sequences ofclones that may be overrepresented
in a cDNA library due to amplification. With additional
advances in cDNA library construction and screening, the
technology exists for large-scale shotgun sequencing of
cDNA, whereby it should be possible to identify a "gene
profile" of the expressed cDNAs for a given tissue or cell.
These data could then be compared to a gene profile of the
tissue at a later developmental or disease state to identify
changes in gene expression.
Another Approach to Development. Clearly, the analysis of
large numbers of cDNAs from a particular tissue affords the
opportunity to generate many markers for cellular differen-
tion. When tumors or normal cells fractionated by physio-
logical properties (e.g., by cell sorting) from a particular
tissue are tested for the expression of these cDNA markers,
distinct cell lineages and individual stages within particular
lineages may be defined (5). Accordingly, the sequence and
expression analysis of cDNAs from complex organs such as
the breast, prostate, or BM may afford a powerful new
approach to studying the normal and pathological develop-
ment of complex organs and organ systems.
Note. While this paper was in preparation, the sequence of PSBM43
(unknown) appeared in the data bases as an unpublished human
differentiation-dependent A4 protein (HUMA4).
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